Brazil has quietly become one of the more strategically important countries in global clinical research. It offers the advantages of Brazil’s large, genetically diverse, treatment-naive patient population and an improving regulatory framework by ANVISA. These factors suggest that careful planning is essential for setting up or upgrading a Contract Research Organization (CRO) in Brazil to meet global GCP standards, rather than hastily following a checklist.
Brazil
Brazil’s clinical research law has been significantly updated, with ANVISA refining the framework for CROs. Key changes include clearer post-trial access obligations for investigational drugs and the ability to import investigational products while the regulatory dossier is still under review, reducing the time between ANVISA authorization and study commencement. This operational shift benefits CROs that have established import and storage protocols.
At the same time, Brazil’s GCP expectations align closely with ICH E6, particularly with the transition to ICH E6(R3), which is redefining global quality management standards. A CRO established or updated in Brazil must adhere to these standards from the outset, rather than being modified later for data tailored for FDA, EMA, or other international submissions.
ANVISA, CEP, and CONEP
Clinical research oversight in Brazil is managed by ANVISA, the National Health Surveillance Agency, which oversees GCP, GMP, and GLP certification, as well as broader regulation of pharmaceuticals and medical devices. Trial applications also undergo ethics reviews conducted by local research ethics committees (CEP) and, depending on their risk classification and scope, by the national research ethics commission (CONEP).
This dual-track structure of regulatory review through ANVISA and ethics review through CEP/CONEP is unique to Brazil, despite resembling processes in other major markets. A CRO that approaches this as a simple checklist may misinterpret the division of responsibilities between CEP and CONEP, risking delays that sponsors cannot afford during study startup.
CRO Upgradation in Brazil
Setting up a GCP-compliant CRO in Brazil requires establishing multiple interconnected systems rather than achieving a single milestone.
- A QMS is fundamental, outlining the creation, version control, and training of SOPs, capturing and investigating deviations, and integrating quality metrics into operational decisions. Without a proper QMS, a CRO cannot be considered GCP-compliant, regardless of its SOP documentation.
- Brazil’s research infrastructure is robust yet uneven, with significant differences in site capability between major cities like São Paulo and Rio compared to smaller regional centers. A CRO must implement a thorough, consistent process for evaluating site feasibility, investigator expertise, and staff GCP training prior to site activation.
- With ANVISA’s updated import allowances for investigational products during dossier review, CROs with established compliant storage and documentation can benefit from accelerated timelines. However, those lacking operational readiness may not fully leverage this regulatory flexibility.
- Data management and monitoring infrastructure must ensure that systems like EDC and safety databases are validated and secure, regardless of whether a CRO uses on-site monitoring, a risk-based model, or a hybrid approach. These systems must meet the requirements of ANVISA and any relevant international regulators.
- Pharmacovigilance capabilities, including adverse event detection, causality assessment, and expedited reporting, must be established from the outset with the first patient enrolled, rather than being developed retroactively after a safety signal emerges.
CRO Setup in Brazil
Setting up a new CRO differs from upgrading an existing one, although they share several components. An established CRO typically has staff, sites, and experience but may lack the required documentation rigor, quality infrastructure, or therapeutic breadth for submissions to major global regulators like the FDA, EMA, MHRA, and ANVISA.
Upgradation work focuses on enhancing the documentation system for international standards, improving the quality management system for consistent decision-making, and expanding operational capabilities to support diverse study types. Resistance to change is notable in organizations with entrenched practices compared to those starting anew.
Common Pitfalls in Both Setup and Upgradation
- Treating GCP compliance as a document highlights the importance of having SOPs that are not only in place but actively trained, followed, and audited. Neglecting this leads to gaps that inspectors easily identify.
- Applying a uniform site management approach across Brazil’s diverse regions often leads to inconsistent site performance due to the underestimation of regional variations.
- Building solely for ANVISA restricts a CRO’s long-term value for sponsors engaged in multinational programs, as it does not consider the data package’s compatibility with FDA or EMA standards.
- Brazil’s evolving import allowances significantly impact study startup speed, highlighting the critical and often neglected issue of underinvesting in import and logistics infrastructure, which is also one of the more addressable challenges.
Zenovel assists organizations in Brazil in developing and enhancing CROs to comply with global GCP standards. Their services include quality management system development, documentation frameworks, site and investigator qualification, and operational infrastructure for obtaining regulatory approvals from ANVISA and other international bodies. More information can be found on the www.zenovel.com website.
